Ivanesemab
Productby Summit Therapeutics
Heard in 4 episodes across 3 shows since Sep 2026
Ivanesemab appears to be an investigational therapeutic antibody candidate. Available search evidence indicates it was designed with an extended half-life and evaluated in the context of oncology drug development, but reliable public information about its precise target, indication, development status, and formulation is limited.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 1 |
| Oct 2026 | 1 |
| Nov 2026 | 2 |
Email alert
Email me when Ivanesemab comes up on a podcast
One email a week at most, with the new episodes that mention Ivanesemab. Free, no account needed, unsubscribe in one click.
What experts have said about Ivanesemab
1 statement · 1 negative
The FDA rejected Summit’s ibanesimab application after warning that survival benefit was needed.
“the FDA told Summit that without a survival benefit, you shouldn't file this drug for approval. Summit did that anyway, didn't listen to the FDA, filed the drug, and lo and behold, we found out over the weekend that the FDA rejected it.”
Open the episode · 422: FDA's search for a new leader, and China's largest drugmakersListen at 10:35
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
4 episodes featuring Ivanesemab, newest first
- Nov 20, 2026
Biotech weighs AI disruption against a stronger 2027 deal cycleBiotech HangoutNov 20, 2026 - Nov 20, 2026
FDA leadership falters as China biotech reshapes drug competitionThe Readout LoudNov 20, 2026 - Oct 30, 2026
Biotech weighs AI promise against biology’s stubborn bottlenecksBiotech HangoutOct 30, 2026 - Sep 29, 2026
AI safety delays test labs’ revenue ambitionsWSJ What’s NewsSep 29, 2026